Stem Cell Transplants From Donors in Relapsed or Treatment-Resistant Multiple Myeloma
Observes how donor stem cell transplants are used in adults with relapsed multiple myeloma.
Plain-language title generated from the registry record
Registry title: Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma
Key facts
- Where
- Chieti, ItalySee the site
Where in Italy
- Dipartimento di Medicina e Scienze dell'Invecchiamento, Università degli Studi "G. d'Annunzio" di Chieti - PescaraChieti, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Università degli Studi 'G. d'Annunzio' Chieti e Pescara
- Trial code
- NCT07777406
- Record updated
- 20 August 2026
- Original description
A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.Read full original descriptionShow less
Studio Real-life Sull'Utilizzo Del Trapianto Allogenico di Cellule Staminali Ematopoietiche in Pazienti Affetti da Mieloma Multiplo Recidivato Refrattario
A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.
Inclusion: patients diagnosed with relapsed/refractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation; Age ≥ 18 years; Signature of the informed consent form (where possible).
Exclusion: Patients who have not undergone allogeneic hematopoietic stem cell transplantation; Age < 18 years; Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia.